Drug intelligence / Profile preview

Bifidobacterium infantum b8762

Development stage: Preclinical
Lead developer: Soochow University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium infantum b8762 is a specific probiotic strain of the species *Bifidobacterium infantum* (also classified as *Bifidobacterium longum* subsp. *infantum*) currently under investigation for its therapeutic potential in metabolic and endocrine disorders. Developed by researchers at Soochow University, this strain is being evaluated in clinical trials for the treatment of obesity and polycystic ovary syndrome (PCOS), often in conjunction with dietary interventions like the ketogenic diet. The mechanism of action involves the modulation of the host's gut microbiota, which is thought to lead to improvements in intestinal barrier integrity, a reduction in systemic pro-inflammatory cytokines, and enhanced insulin sensitivity, thereby addressing the hormonal imbalances and metabolic dysfunction characteristic of PCOS.

Other names: Bifidobacterium longum subsp. infantum b8762

Beyond the preview

Go deeper on Bifidobacterium infantum b8762.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium infantum b8762.

Explore the full profile